Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases

ABSTRACT Background: About 80% of breast cancer (BC) cases express estrogen receptor (ER), which has been correlated with good prognosis and response to estrogen deprivation Aim: To characterize ER positive advanced BC (ABC) patients treated at our institution assessing the impact of clinical pre-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sánchez,César, Domínguez,Francisco, Galindo,Héctor, Camus,Mauricio, Oddo,David, Villarroel,Alejandra, Razmilic,Dravna, Peña,José, Navarro,María Elena, Medina,Lidia, Merino,Tomás, Briones,Juan, Acevedo,Francisco
Lenguaje:	English
Publicado:	Sociedad Médica de Santiago 2020
Materias:	Breast Neoplasms Neoplasm Metastasis Prognosis Receptors, Estrogen
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000901233
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872020000901233
record_format	dspace
spelling	oai:scielo:S0034-988720200009012332020-12-26Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 casesSánchez,CésarDomínguez,FranciscoGalindo,HéctorCamus,MauricioOddo,DavidVillarroel,AlejandraRazmilic,DravnaPeña,JoséNavarro,María ElenaMedina,LidiaMerino,TomásBriones,JuanAcevedo,Francisco Breast Neoplasms Neoplasm Metastasis Prognosis Receptors, Estrogen ABSTRACT Background: About 80% of breast cancer (BC) cases express estrogen receptor (ER), which has been correlated with good prognosis and response to estrogen deprivation Aim: To characterize ER positive advanced BC (ABC) patients treated at our institution assessing the impact of clinical pre-sentation (stage IV, de novo disease at diagnosis versus systemic recurrence) and BC subtype on survival rates. Material and Methods: We evaluated 211 ER+ advanced BC (ABC) patients, treated between 1997 and 2017. Results: The median overall survival (OS) was 37 months. Median OS for the period 1997/2006 and 2007/2017 were 33 and 42 months, respectively (p = 0.47). Luminal A, ABC stage IV disease at diagnosis displayed better OS rates than Luminal B stage IV tumors (100 and 32 months respectively, p < 0.01). Conclusions: Clinical presentation (stage IV vs. systemic recurrence) and tumor subtype are key determinants of OS in ABC.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.148 n.9 20202020-09-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000901233en10.4067/S0034-98872020000901233
institution	Scielo Chile
collection	Scielo Chile
language	English
topic	Breast Neoplasms Neoplasm Metastasis Prognosis Receptors, Estrogen
spellingShingle	Breast Neoplasms Neoplasm Metastasis Prognosis Receptors, Estrogen Sánchez,César Domínguez,Francisco Galindo,Héctor Camus,Mauricio Oddo,David Villarroel,Alejandra Razmilic,Dravna Peña,José Navarro,María Elena Medina,Lidia Merino,Tomás Briones,Juan Acevedo,Francisco Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases
description	ABSTRACT Background: About 80% of breast cancer (BC) cases express estrogen receptor (ER), which has been correlated with good prognosis and response to estrogen deprivation Aim: To characterize ER positive advanced BC (ABC) patients treated at our institution assessing the impact of clinical pre-sentation (stage IV, de novo disease at diagnosis versus systemic recurrence) and BC subtype on survival rates. Material and Methods: We evaluated 211 ER+ advanced BC (ABC) patients, treated between 1997 and 2017. Results: The median overall survival (OS) was 37 months. Median OS for the period 1997/2006 and 2007/2017 were 33 and 42 months, respectively (p = 0.47). Luminal A, ABC stage IV disease at diagnosis displayed better OS rates than Luminal B stage IV tumors (100 and 32 months respectively, p < 0.01). Conclusions: Clinical presentation (stage IV vs. systemic recurrence) and tumor subtype are key determinants of OS in ABC.
author	Sánchez,César Domínguez,Francisco Galindo,Héctor Camus,Mauricio Oddo,David Villarroel,Alejandra Razmilic,Dravna Peña,José Navarro,María Elena Medina,Lidia Merino,Tomás Briones,Juan Acevedo,Francisco
author_facet	Sánchez,César Domínguez,Francisco Galindo,Héctor Camus,Mauricio Oddo,David Villarroel,Alejandra Razmilic,Dravna Peña,José Navarro,María Elena Medina,Lidia Merino,Tomás Briones,Juan Acevedo,Francisco
author_sort	Sánchez,César
title	Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases
title_short	Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases
title_full	Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases
title_fullStr	Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases
title_full_unstemmed	Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases
title_sort	survival rates of advanced estrogen-receptor positive breast cancer. analysis of 211 cases
publisher	Sociedad Médica de Santiago
publishDate	2020
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000901233
work_keys_str_mv	AT sanchezcesar survivalratesofadvancedestrogenreceptorpositivebreastcanceranalysisof211cases AT dominguezfrancisco survivalratesofadvancedestrogenreceptorpositivebreastcanceranalysisof211cases AT galindohector survivalratesofadvancedestrogenreceptorpositivebreastcanceranalysisof211cases AT camusmauricio survivalratesofadvancedestrogenreceptorpositivebreastcanceranalysisof211cases AT oddodavid survivalratesofadvancedestrogenreceptorpositivebreastcanceranalysisof211cases AT villarroelalejandra survivalratesofadvancedestrogenreceptorpositivebreastcanceranalysisof211cases AT razmilicdravna survivalratesofadvancedestrogenreceptorpositivebreastcanceranalysisof211cases AT penajose survivalratesofadvancedestrogenreceptorpositivebreastcanceranalysisof211cases AT navarromariaelena survivalratesofadvancedestrogenreceptorpositivebreastcanceranalysisof211cases AT medinalidia survivalratesofadvancedestrogenreceptorpositivebreastcanceranalysisof211cases AT merinotomas survivalratesofadvancedestrogenreceptorpositivebreastcanceranalysisof211cases AT brionesjuan survivalratesofadvancedestrogenreceptorpositivebreastcanceranalysisof211cases AT acevedofrancisco survivalratesofadvancedestrogenreceptorpositivebreastcanceranalysisof211cases
_version_	1718437149606412288

Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases

Ejemplares similares